Veradermics reported a net loss of $23.5 million for the quarter ended June 30, 2026, compared to a $15.6 million loss in the prior year period. Research and development expenses increased to $18.6 million from $14.3 million, while general and administrative expenses rose sharply to $10.9 million from $1.7 million due to commercial readiness costs and headcount growth. The company ended the quarter with $819.9 million in cash, cash equivalents, and marketable securities, following a follow-on offering that raised approximately $472.0 million in May 2026. Clinically, Veradermics completed enrollment for its registration-directed Phase 2/3 Study '306' evaluating VDPHL01 in female pattern hair loss, with topline data expected in the first half of 2027. Topline results from the confirmatory Phase 3 Study '304' in men and 12-month data from Study '302' are anticipated in the second half of 2026. Veradermics is a late-stage biopharmaceutical company developing innovative therapeutics for pattern hair loss.

Veradermics, Inc. announced positive topline results from its Phase 2 'Study 207' clinical trial evaluating VDPHL01, an extended-release oral minoxidil formulation, for females with mild-to-moderate pattern hair loss. In the 6-month assessment, female participants receiving 4.5 mg doses once or twice daily showed an average non-vellus hair count increase of 22.7 hairs/cm² and 23.3 hairs/cm², respectively. Additionally, 88.9% of the once-daily arm and 90.0% of the twice-daily arm reported improved or much improved hair coverage on the Androgenetic Alopecia Impact Rating Scale. The treatment was generally well tolerated with no treatment-related serious adverse events or cardiac-related adverse events of special interest. Veradermics is a biotechnology company developing hair loss treatments.